On March 24, 2003, the Michigan Supreme Court upheld a Michigan statute that precludes design-defect tort actions against the manufacturer of a drug that has been approved for sale by the Food and Drug Administration (FDA). The decision was a victory for WLF, which filed a brief urging that the statute be upheld. The court agreed with WLF that the Michigan legislature acted properly in adopting the statute and that it did not violate a state constitutional provision that prohibits the legislature from delegating its powers to a federal administrative agency.